Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCCCTS: Pyrimethamine Regimens for Congenital Toxoplasmosis
NCT00004317Phase 4Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2000
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pyrimethamine in congenital toxoplasmosis (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Persistent motor abnormality at 20 years, Vision outcomes at 20 years and 4 more. Started Jul 2000; status: recruiting.
02
Drugs
pyrimethamine
03
Conditions
congenital toxoplasmosis
Beyond the preview
Go deeper on NCT00004317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004317.